Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Mitoxantrone
Drug ID BADD_D01480
Description An anthracenedione-derived antineoplastic agent.
Indications and Usage For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
Marketing Status approved; investigational
ATC Code L01DB07
DrugBank ID DB01204
KEGG ID D08224
MeSH ID D008942
PubChem ID 4212
TTD Drug ID D0R3JB
NDC Product Code 61703-343
UNII BZ114NVM5P
Synonyms Mitoxantrone | Mitozantrone | DHAQ | NSC-279836 | NSC 279836 | NSC279836 | NSC-287836 | NSC 287836 | NSC287836 | NSC-299195 | NSC 299195 | NSC299195 | NSC-301739 | NSC 301739 | NSC301739 | NSC-301739D | NSC 301739D | NSC301739D | Mitroxone | Pralifan | CL-232325 | CL 232325 | CL232325 | Mitoxantrone Acetate | Acetate, Mitoxantrone | Mitoxantrone Hydrochloride | Hydrochloride, Mitoxantrone | Novantrone | Ralenova | Novantron | Onkotrone
Chemical Information
Molecular Formula C22H28N4O6
CAS Registry Number 65271-80-9
SMILES C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Breast cancer stage IV21.05.01.010; 16.10.01.003--Not Available
Cardiac failure02.05.01.0010.000224%
Cardiac failure congestive02.05.01.0020.000168%Not Available
Cardiogenic shock24.06.02.006; 02.05.01.0030.000112%Not Available
Cardiomyopathy02.04.01.0010.000336%Not Available
Cardiovascular disorder02.11.01.010; 24.03.02.009--Not Available
Catheterisation cardiac abnormal13.14.07.001--Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.12.02.003--Not Available
Chills15.05.03.016; 08.01.09.001--
Chromaturia20.02.01.002--
Chromosome banding abnormal13.23.02.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Cough22.02.03.001--
Death08.04.01.001--
Dehydration14.05.05.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.0010.000168%
Discomfort08.01.08.003--Not Available
Drug ineffective08.06.01.0060.000280%Not Available
Drug interaction08.06.03.0010.000112%Not Available
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.0040.000168%
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Electrocardiogram abnormal13.14.05.001--Not Available
Endocrine disorder05.09.01.001--Not Available
Endometritis21.14.01.002; 11.01.10.005--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene